報價延遲最少15分鐘:2024/12/23 22:29 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
43.93 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.66/-4.08
|
|
企業價值
8.22B
|
| 資產負債 |
|
每股賬面淨值
8.48
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
11.58M
|
|
每股收益
0.14
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:29 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |